Skip to main content
SpringerLink
Log in

Ranibizumab and Other VEGF Antagonists for Diabetic Macular Edema

  • Chapter
  • First Online:
Book cover Visual Dysfunction in Diabetes

Part of the book series: Ophthalmology Research ((OPHRES))

  • 1042 Accesses

Abstract

Vision loss from diabetic retinopathy has a tremendous impact on society as it is the most prevalent cause of vision loss in the working-age population of developed countries. By 2025, it is expected that there will be more than 300 million people worldwide with diabetes. While severe loss can be caused by vitreous hemorrhage or tractional retinal detachment, diabetic macular edema (DME) is the most common cause of moderate vision loss. The prevalence of DME is estimated at 10–25% of the diabetic population, with this percentage being higher in those patients with more severe retinopathy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. WHO. Fact sheet no. 138. Geneva: WHO; 2002.

    Google Scholar 

  2. Klein R. Retinopathy in a population-based study. Trans Am Ophthalmol Soc. 1992;90:561–94.

    PubMed  CAS  Google Scholar 

  3. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998;105(10):1801–15.

    Article  PubMed  CAS  Google Scholar 

  4. Hardy RA, Crawford JB. Retina. In: Vaughn D, Asbury T, Riordan-Eva P, editors. General ophthalmology. 15th ed. Stamford: Appleton & Lange; 1999. p. 178–99.

    Google Scholar 

  5. Moore J, Bagley S, Ireland G, McLeod D, Boulton ME. Three dimensional analysis of microaneurysms in the human diabetic retina. J Anat. 1999;194(Pt 1):89–100.

    Article  PubMed  Google Scholar 

  6. Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol. 1999;14(4):223–32.

    Article  PubMed  CAS  Google Scholar 

  7. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997;46(9):1473–80.

    Article  PubMed  CAS  Google Scholar 

  8. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219(4587):983–5.

    Article  PubMed  CAS  Google Scholar 

  9. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 2005;109(3):227–41.

    Article  CAS  Google Scholar 

  10. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular ­endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996;103(11):1820–8.

    PubMed  CAS  Google Scholar 

  11. Cunningham Jr ET, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112(10):1747–57.

    Article  PubMed  Google Scholar 

  12. Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. ­Ophthalmology. 2003;110(9):1690–6.

    Article  PubMed  Google Scholar 

  13. Nguyen QD, Shah SM, Van Anden E, Sung JU, Vitale S, Campochiaro PA. Supplemental oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci. 2004;45(2):617–24.

    Article  PubMed  Google Scholar 

  14. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16(9):4604–13.

    PubMed  CAS  Google Scholar 

  15. Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest. 1998;101(6):1219–24.

    Article  PubMed  CAS  Google Scholar 

  16. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes. 1998;47(12):1953–9.

    Article  PubMed  CAS  Google Scholar 

  17. Ozaki H, Hayashi H, Vinores SA, Moromizato Y, Campochiaro PA, Oshima K. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res. 1997;64(4):505–17.

    Article  PubMed  CAS  Google Scholar 

  18. Campochiaro PA. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci. 2004;45(3):922–31.

    Article  PubMed  Google Scholar 

  19. Fabbro D, Buchdunger E, Wood J, et al. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther. 1999;82(2–3):293–301.

    Article  PubMed  CAS  Google Scholar 

  20. Fabbro D, Ruetz S, Bodis S, et al. PKC412–a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des. 2000;15(1):17–28.

    PubMed  CAS  Google Scholar 

  21. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103(12):1796–806.

    Article  Google Scholar 

  22. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115(9):1447–9, 1449e1–10.

    Google Scholar 

  23. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18(12):1450–2.

    PubMed  CAS  Google Scholar 

  24. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341(2–3):309–15.

    Article  PubMed  CAS  Google Scholar 

  25. Nauck M, Roth M, Tamm M, et al. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol. 1997;16(4):398–406.

    PubMed  CAS  Google Scholar 

  26. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113(9):1533–8.

    Article  PubMed  Google Scholar 

  27. Presta LG, Chen H, O’Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593–9.

    PubMed  CAS  Google Scholar 

  28. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF ­antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol. 1999;293(4):865–81.

    Article  PubMed  CAS  Google Scholar 

  29. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–31.

    Article  PubMed  CAS  Google Scholar 

  30. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–44.

    Article  PubMed  CAS  Google Scholar 

  31. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006;142(6):961–9.

    Article  PubMed  CAS  Google Scholar 

  32. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology. 2006;113(10):1706–12.

    Article  PubMed  Google Scholar 

  33. Nguyen Q, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. Primary end point (six months) results of the ranibizumab for edema of the Macula in Diabetes (READ-2) Study. Ophthalmology. 2009;116(11):2175–81.

    Article  PubMed  Google Scholar 

  34. Schmid KE, Neumaier-Ammerer B, Stolba U, Binder S. Effect of grid laser photocoagulation in diffuse diabetic macular edema in correlation to glycosylated haemoglobin (HbA1c). Graefes Arch Clin Exp Ophthalmol. 2006;244(11):1446–52.

    Article  PubMed  CAS  Google Scholar 

  35. Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805–16.

    Article  PubMed  CAS  Google Scholar 

  36. Scott IU, Edwards AR, Beck RW, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114(10):1860–7.

    Article  PubMed  Google Scholar 

  37. Mittra RA, Savino PJ, editors. ASRS 2006 preferences and trends membership survey. Chico: American Society of Retina Specialists; 2007.

    Google Scholar 

  38. Arevalo JF, Sanchez JG, Fromow-Guerra J, et al. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol. 2009;247(6):735–43.

    Article  PubMed  CAS  Google Scholar 

  39. Kook D, Wolf A, Kreutzer T, et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina. 2008;28(8):1053–60.

    Article  PubMed  Google Scholar 

  40. Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology. 2009;116(6):1142–50.

    Article  PubMed  Google Scholar 

  41. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99(17):11393–8.

    Article  PubMed  CAS  Google Scholar 

  42. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008;92(5):667–8.

    Article  PubMed  CAS  Google Scholar 

  43. Kaiser PK. Vascular endothelial growth factor Trap-Eye for diabetic macular oedema. Br J Ophthalmol. 2009;93(2):135–6.

    Article  PubMed  Google Scholar 

  44. Do DV, Nguyen QD, Shah SM, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br J Ophthalmol. 2009;93(2):144–9.

    Article  PubMed  CAS  Google Scholar 

  45. Browning DJ, Altaweel MM, Bressler NM, Bressler SB, Scott IU. Diabetic macular edema: what is focal and what is diffuse? Am J Ophthalmol. 2008;146(5):649–55, 655e641–6.

    Google Scholar 

  46. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116(1):73–9.

    Article  PubMed  Google Scholar 

  47. Hoekzema R, Verhagen C, van Haren M, Kijlstra A. Endotoxin-induced uveitis in the rat. The significance of intraocular interleukin-6. Invest Ophthalmol Vis Sci. 1992;33(3):532–9.

    PubMed  CAS  Google Scholar 

  48. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996;271(2):736–41.

    Article  PubMed  CAS  Google Scholar 

  49. Gardner TW, Antonetti DA. Novel potential mechanisms for diabetic macular edema: leveraging new investigational approaches. Curr Diab Rep. 2008;8(4):263–9.

    Article  PubMed  CAS  Google Scholar 

  50. Woolard J, Wang WY, Bevan HS, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004;64(21):7822–35.

    Article  PubMed  CAS  Google Scholar 

  51. Varey AH, Rennel ES, Qiu Y, et al. VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer. 2008;98(8):1366–79.

    Article  PubMed  CAS  Google Scholar 

  52. Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia. 2005;48(11):2422–7.

    Article  PubMed  CAS  Google Scholar 

  53. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–77. www.drcr.net.

    Google Scholar 

  54. Bernbaum M, Albert SG, Duckro PN. Psychosocial profiles in patients with visual impairment due to diabetic retinopathy. Diabetes Care. 1988;11(7):551–7.

    Article  PubMed  CAS  Google Scholar 

  55. Bernbaum M, Albert SG, Duckro PN, Merkel W. Personal and family stress in individuals with diabetes and vision loss. J Clin Psychol. 1993;49(5):670–7.

    Article  PubMed  CAS  Google Scholar 

  56. Wulsin LR, Jacobson AM, Rand LI. Psychosocial aspects of diabetic retinopathy. Diabetes Care. 1987;10(3):367–73.

    Article  PubMed  CAS  Google Scholar 

  57. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119(7):1050–8.

    PubMed  CAS  Google Scholar 

  58. Miskala PH, Bressler NM, Meinert CL. Relative contributions of reduced vision and general health to NEI-VFQ scores in patients with neovascular age-related macular degeneration. Arch Ophthalmol. 2004;122(5):758–66.

    Article  PubMed  Google Scholar 

  59. Clemons TE, Chew EY, Bressler SB, McBee W. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS report no. 10. Arch Ophthalmol. 2003;121(2):211–7.

    PubMed  Google Scholar 

  60. Klein R, Moss SE, Klein BE, Gutierrez P, Mangione CM. The NEI-VFQ-25 in people with long-term type 1 diabetes mellitus: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol. 2001;119(5):733–40.

    PubMed  CAS  Google Scholar 

  61. Jampel HD, Schwartz A, Pollack I, Abrams D, Weiss H, Miller R. Glaucoma patients’ assessment of their visual function and quality of life. J Glaucoma. 2002;11(2):154–63.

    Article  PubMed  Google Scholar 

  62. Deramo VA, Cox TA, Syed AB, Lee PP, Fekrat S. Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2003;121(9):1297–302.

    Article  PubMed  Google Scholar 

  63. Cusick M, SanGiovanni JP, Chew EY, et al. Central visual function and the NEI-VFQ-25 near and distance activities subscale scores in people with type 1 and 2 diabetes. Am J Ophthalmol. 2005;139(6):1042–50.

    Article  PubMed  Google Scholar 

  64. Bressler NM, Chang TS, Suner IJ, et al. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology. 2010;117(4):747–56e744.

    Google Scholar 

  65. Hariprasad SM, Mieler WF, Grassi M, Green JL, Jager RD, Miller L. Vision-related quality of life in patients with diabetic macular oedema. Br J Ophthalmol. 2008;92(1):89–92.

    Article  PubMed  CAS  Google Scholar 

  66. Lamoureux EL, Tai ES, Thumboo J, et al. Impact of diabetic retinopathy on vision-specific function. Ophthalmology. 2010;117(4):757–65.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA

    Ben J. Kim, Diana V. Do & Quan Dong Nguyen

Authors
  1. Ben J. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diana V. Do
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Quan Dong Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Quan Dong Nguyen .

Editor information

Editors and Affiliations

  1. Milton S. Hershey Medical Center, Dept. Neural and Behavioral Sciences, Penn State College of Medicine, University Drive 500, Hershey, 17033, Pennsylvania, USA

    Joyce Tombran-Tink

  2. Milton S. Hershey Medical Center, Dept. Neural and Behavioral Sciences, Penn State College of Medicine, University Drive 500, Hershey, 17033, Pennsylvania, USA

    Colin J. Barnstable

  3. Molecular and Integrative Physiology, Ophthalmology and Visual Sciences, Kellogg Eye Center, Wall Street 1000, Ann Arbor, 17033-2390, Michigan, USA

    Thomas W. Gardner

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Kim, B.J., Do, D.V., Nguyen, Q.D. (2012). Ranibizumab and Other VEGF Antagonists for Diabetic Macular Edema. In: Tombran-Tink, J., Barnstable, C., Gardner, T. (eds) Visual Dysfunction in Diabetes. Ophthalmology Research. Springer, New York, NY. https://doi.org/10.1007/978-1-60761-150-9_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-150-9_17

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-60761-149-3

  • Online ISBN: 978-1-60761-150-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation